A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome‐positive chronic myeloid leukemia in chronic phase: ENESTKorea

Although nilotinib has improved efficacy compared to imatinib, suboptimal response and intolerable adverse events (AEs) limit its effectiveness in many patients with chronic myeloid leukemia in chronic phase (CML‐CP). We investigated the 2‐year efficacy and safety of nilotinib and their relationship...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Junghoon, Koh, Youngil, Yoon, Seo Hyun, Cho, Joo‐Youn, Kim, Dae‐Young, Lee, Kyoo‐Hyung, Kim, Hyeong‐Joon, Ahn, Jae‐Sook, Kim, Yeo‐Kyeoung, Park, Jinny, Sohn, Sang‐Kyun, Moon, Joon Ho, Lee, Yoo Jin, Yoon, Seonghae, Lee, Jeong‐Ok, Cheong, June‐Won, Kim, Kyoung Ha, Kim, Sung‐Hyun, Kim, Hoon‐Gu, Kim, Hawk, Nam, Seung‐Hyun, Do, Young Rok, Park, Sang‐Gon, Park, Seong Kyu, Bae, Sung Hwa, Song, Hun Ho, Shin, Dong‐Yeop, Oh, Doyeun, Kim, Min Kyoung, Jung, Chul Won, Park, Seonyang, Kim, Inho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943463/
https://www.ncbi.nlm.nih.gov/pubmed/29577674
http://dx.doi.org/10.1002/cam4.1450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943463/
https://www.ncbi.nlm.nih.gov/pubmed/29577674
http://dx.doi.org/10.1002/cam4.1450

Ejemplares similares